AQUESTIVE THERAPEUTICS

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

12 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

04 Nov 2024 15:36:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting

25 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm™ (epinephrine) Sublingual Film

24 Oct 2024 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET

21 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day

27 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th

09 Sep 2024 07:15:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences

22 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™

14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

06 Aug 2024 15:22:19 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study

25 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET

23 Jul 2024 07:00:01 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism

27 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film

25 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

18 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities

03 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference

28 May 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

07 May 2024 15:19:11 By Nasdaq GlobeNewswire

Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film

29 Apr 2024 06:00:00 By Nasdaq GlobeNewswire